Amol Akhade: What IO combination will u prefer for first-line Advanced BTC?
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X, commenting on his earlier post:
“Final Results.
What IO combination will u prefer for first-line Advanced BTC?
156 votes.
As per comments,
Early movers advantage to Topaz?
Across Atlantic, Durva is more preferred, may be due to earlier approval.
Indian oncologist probably favor pembrolizumab, due to more experience of using it and with better Patient assistance programs, leading to lesser cost.
Overall,
- 33 % preferred Gem cis durva
- 26 % will use Gem cis plus pembrolizumab.
- 24 % rightly agree that – both are equally good or bad and one can use any of it.
- 17 % feel that magnitude of benifit is not much for additional cost and toxicity.
I do feel, as an approved indication, option of IO should be given to patients with BTC with disclosure that only some of the patients benifit and more importantly, we don’t know who these patients are.
PdL 1 is most imprecise biomarker in precision Oncology ironically and we need better biomarkers to know which pts will have some long-term benifit with additional IO.”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals.
He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023